3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
2
Esophageal Neoplasms
2
Breast Neoplasms
2
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Metastatic
1
Interventions
pembrolizumab
21
lenvatinib
8
Paclitaxel
5
patritumab deruxtecan
3
enfortumab vedotin
2
belzutifan
2
Tretinoin
2
Surgical Procedures, Operative
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Capecitabine
2
tremelimumab
1
trametinib
1
poly ICLC
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
dabrafenib
1
Ramucirumab
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Pemetrexed
1
Levoleucovorin
1
Immunotherapy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
patritumab deruxtecan
×
Clear all
NCT06469944
2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
160 enrolled
NCT04165070
2026-05-18
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
450 enrolled
NCT06445972
2026-05-12
MK-3475-06D
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
210 enrolled